BIO-TECHNE TO PRESENT AT THE 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that Kim Kelderman, current COO, and CEO effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The company is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, generating approximately $1.1 billion in net sales in fiscal 2023 with around 3,100 employees worldwide.

MINNEAPOLIS, Dec. 21, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024, will present at the 42^nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide.

Contact:	David Clair, Vice President, Investor Relations & Corporate Development
	david.clair@bio-techne.com
	612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302019228.html

SOURCE Bio-Techne Corporation

FAQ

What was announced by Bio-Techne Corporation (NASDAQ: TECH)?

Bio-Techne Corporation announced that Kim Kelderman, current COO, and CEO effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

What does Bio-Techne Corporation (NASDAQ: TECH) specialize in?

Bio-Techne Corporation specializes in developing and manufacturing high-quality purified proteins and reagent solutions, including cytokines, growth factors, antibodies, immunoassays, and more.

How much did Bio-Techne Corporation (NASDAQ: TECH) generate in net sales in fiscal 2023?

Bio-Techne Corporation generated approximately $1.1 billion in net sales in fiscal 2023.

How many employees does Bio-Techne Corporation (NASDAQ: TECH) have worldwide?

Bio-Techne Corporation has approximately 3,100 employees worldwide.